Corcept Therapeutics Incorporated (NASDAQ:CORT) said that the primary endpoint was met in the treatment phase of CATALYST, a ...

Corcept Therapeutics drug Korlym, which treats hypercortisolism and difficult-to-control type 2 diabetes, met its primary endpoint in the treatment phase of CATALYST, a randomized, double-blind, ...

Over a decade into selling Korlym to treat endogenous hypercortisolism, also known as Cushing syndrome, Corcept Therapeutics ...

Also Read: Corcept Therapeutics’ Commercial Drug Korlym Sales Impress Despite Increased Competition, Analyst Boosts Price Forecast CATALYST is a prospective Phase 4 study with two parts.

Shares of Corcept Therapeutics Incorporated CORT have rallied 60.7% in the past three months against the industry’s decline ...

The company’s sole-marketed drug, Korlym (mifepristone), which is approved for treating Cushing's syndrome, has been performing well. The drug has been witnessing a strong demand in the past ...

The study found that the drug Korlym significantly improved blood sugar levels in affected patients. According to InvestingPro analysis, the company appears to be trading above its Fair Value ...

Corcept Therapeutics specializes in cortisol-modulating drugs, with Korlym targeting Cushing Syndrome and a promising pipeline, including Relacorilant, for diabetes and ovarian cancer. CORT's ...

The study found that the drug Korlym significantly improved blood sugar levels in affected patients. According to InvestingPro analysis, the company appears to be trading above its Fair Value, though ...